Active-ingredient Dossier
Quetiapine Fumarate
Active-ingredient Dossier for Quetiapine Fumarate (atypical antipsychotic). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: SEROQUEL
- Brand: APX-QUETIAPINE XR
- Brand: DELUCON
- Brand: QUETIA
- Brand: QUETIAPINE
- Brand: SYQUET
- Therapeutic area: Psychiatry
- Therapeutic area: Neurology
What is
Quetiapine Fumarate Quetiapine Fumarate is an atypical antipsychotic.
Australian brands containing
Quetiapine Fumarate — SEROQUEL — QUETIAPINE — APX-QUETIAPINE — APX-QUETIAPINE XR — DELUCON — QUETIA — QUETIAPINE SANDOZ — QUETIAPINE-WGR — QUETIN — SEQUASE — SYQUET
Therapeutic areas
Quetiapine Fumarate is registered in Neurology, with 21 brands containing this ingredient on the ARTG.
Sponsor landscape
The ingredient is marketed by nine sponsors: Arrotex Pharmaceuticals, Accord Healthcare, Luye Pharma, GM Pharma, Pharmacor, and Strides Pharma Science.
PBS and regulatory activity
One brand containing Quetiapine Fumarate has PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome on record is from 1 March 2018, with two brands having PBAC outcomes recorded. No AusPARs are on record for this ingredient.